Wedbush Predicts Higher Earnings for Compass Therapeutics

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Investment analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of Compass Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.32) per share for the year, up from their previous forecast of ($0.39). Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at $0.31 EPS and FY2028 earnings at $1.76 EPS.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03.

A number of other brokerages have also issued reports on CMPX. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Monday. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Monday, September 16th.

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $1.59 on Friday. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34. The company’s 50 day moving average is $1.76 and its 200-day moving average is $1.42.

Institutional Trading of Compass Therapeutics

Several institutional investors have recently modified their holdings of CMPX. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics in the third quarter valued at $25,000. Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics in the 3rd quarter valued at $30,000. SG Americas Securities LLC lifted its holdings in shares of Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after acquiring an additional 5,515 shares during the period. Bleakley Financial Group LLC acquired a new position in Compass Therapeutics in the first quarter worth about $80,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics in the 2nd quarter valued at $41,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.